Connect with us

Technology

Pharmaceutical Contract Research and Manufacturing Market to grow by USD 141.3Billion from 2024-2028, driven by cost-efficient resources in emerging markets, AI-powered report – Technavio

Published

on

NEW YORK, Oct. 7, 2024 /PRNewswire/ — Report on how AI is driving market transformation – The Global Pharmaceutical Contract Research and Manufacturing Market size is estimated to grow by USD 141.3 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  10.87%  during the forecast period. Availability of cost-efficient resources in emerging markets is driving market growth, with a trend towards increasing number of US FDA approved manufacturing facilities. However, stereotypical nature of CMOS  poses a challenge – Key market players include Almac Group Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Catalent Inc., Charles River Laboratories International Inc., Cmic Holdings Co. Ltd, Dr Reddys Laboratories Ltd., ICON plc, IQVIA Holdings Inc., Laboratory Corp. Of America Holdings, Lonza Group Ltd., Lupin Ltd., Novotech Health Holdings, OPTIMAPHARM d.o.o., Parexel International Corp., PCI Pharma Services, Recipharm AB, Samsung Electronics Co. Ltd., Syneos Health Inc., and Thermo Fisher Scientific Inc..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report

Pharmaceutical Contract Research And Manufacturing Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 10.87%

Market growth 2024-2028

USD 141.3 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

9.51

Regional analysis

North America, Asia, Europe, and Rest of World (ROW)

Performing market contribution

Asia at 46%

Key countries

US, China, India, Germany, and UK

Key companies profiled

Almac Group Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Catalent Inc., Charles River Laboratories International Inc., Cmic Holdings Co. Ltd, Dr Reddys Laboratories Ltd., ICON plc, IQVIA Holdings Inc., Laboratory Corp. Of America Holdings, Lonza Group Ltd., Lupin Ltd., Novotech Health Holdings, OPTIMAPHARM d.o.o., Parexel International Corp., PCI Pharma Services, Recipharm AB, Samsung Electronics Co. Ltd., Syneos Health Inc., and Thermo Fisher Scientific Inc.

Market Driver

The Pharmaceutical Contract Research and Manufacturing (CRAM) market is experiencing significant growth due to the increasing number of US FDA-approved manufacturing facilities in emerging economies, particularly China and India. India, with around 400 such facilities, is a top destination for pharmaceutical manufacturing services outsourcing. This includes approximately 230 API and 150 FDF facilities, the highest in any country. China, previously limited to CROs due to stringent regulations on CMOS, has seen a shift with the State Council allowing MAHs to use third-party licensed manufacturers. This change has led to an increase in US FDA-approved facilities and foreign pharmaceutical companies outsourcing drug manufacturing to China. This trend is expected to continue, driving the growth of the global pharmaceutical CRAM market.

The Pharmaceutical Contract Research and Manufacturing (CRM) market is witnessing significant trends in various areas. Generic Drugs are gaining popularity due to their affordability, driving demand for Generic APIs and Formulation Services. Artificial Intelligence is revolutionizing Drug Discovery and Development, enabling faster identification of Drug Candidates. Route Scouting Services and Bioprocess Outsourcing are key areas of focus for Biologics Manufacturing. Regulatory Compliance remains a top priority, with Serialization and Counterfeiting mitigation measures essential. Clinical Trials are outsourced to CROs for cost-effective manufacturing and efficient Clinical Operations. Big Pharmaceutical Companies and Academic Institutes collaborate for innovative Drug Development Services. Advanced manufacturing technologies like Continuous Manufacturing and Digitalization are transforming the Pharmaceutical Ecosystem. Targeted Medication Therapies, Biosimilars, and Personalized Medicines are driving the need for Specialized Services and Cost-effective Manufacturing. Drug Delivery Systems and Clinical Trial Support are crucial for bringing Small Molecule Drugs and Active Pharmaceutical Ingredients to market. Regulatory bodies and industry associations play a vital role in ensuring Quality Control and ensuring the integrity of the Pharmaceutical Supply Chain. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

The pharmaceutical Contract Research and Manufacturing Organizations (CMOs) market in the Asia Pacific region holds the largest share but faces a significant challenge due to limited access to advanced technologies for manufacturing complex drugs, such as biological drugs and vaccines. These CMOs primarily focus on producing small molecule-based generic drugs due to high manufacturing costs and lack of funding. This restricts growth opportunities for small and medium-sized CMOs. Major players like Boehringer Ingelheim, Catalent, and Lonza dominate the market for large-scale production of biological drugs. The absence of advanced technologies and high manufacturing costs in countries like Mexico, South Korea, and Brazil also hinder the growth of CMOs in these regions. Consequently, the global pharmaceutical CRAM market growth may be impeded substantially during the forecast period.The Pharmaceutical Contract Research and Manufacturing (CRM) market faces several challenges in the production of biologics and small molecule drugs. Big Pharma companies and academic institutes rely on CROs for cost-effective manufacturing of targeted medication therapies, including biologics and biosimilars. Manufacturing services for active pharmaceutical ingredients (APIs) and drug formulation require advanced technologies like continuous manufacturing and specialized services for drug delivery systems. Quality control is crucial for producing consistent, high-quality products. CROs must support clinical trial operations and commercial operations, ensuring compliance with quality standards and patient needs. Digitalization and personalized medicines also require specialized expertise. The drug development process involves complex production workflows, from the creation of drug candidates to the manufacturing of oral solids, liquids, emulsions, and more. Meeting the demands of Big Pharma and academic institutes while maintaining cost-effectiveness and quality is a significant challenge for the CRM industry.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview

This pharmaceutical contract research and manufacturing market report extensively covers market segmentation by

Service 1.1 CMO1.2 CROEnd-user 2.1 Big pharmaceuticals2.2 Small and medium-sized pharmaceuticals2.3 Generic pharmaceuticalsGeography 3.1 North America3.2 Asia3.3 Europe3.4 Rest of World (ROW)

1.1 CMO-  The Contract Research and Manufacturing Organizations (CMOs) segment is the largest in the global pharmaceutical CRAM market, accounting for a significant market share. CMOs are entities that manufacture drugs and healthcare products on a contract basis for pharmaceutical companies and biotech firms. Advancements in medical sciences and the growing popularity of specialty medicines, as well as technological developments like nanotechnology and stem cell research, are driving the demand for complex manufacturing processes. These processes require extended resource deployments, leading pharmaceutical giants like Pfizer, Johnson & Johnson, and GlaxoSmithKline to outsource their manufacturing activities to optimize in-house resources. The outsourcing trend is particularly prevalent among pharmaceutical vendors worldwide, resulting in the substantial growth of the CMO segment. Emerging markets, including India, Brazil, China, and Mexico, are major contributors due to their low labor and land costs, making them attractive locations for setting up manufacturing facilities. Generic drug manufacturers in these countries outsource approximately 80% of their production to CMOs. The increasing focus on core competencies and cost reduction, along with the regulatory compliance and research advancement benefits, are fueling the expansion of the CMO segment in the global pharmaceutical CRAM market.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

The Pharmaceutical Contract Research and Manufacturing (CRM) market encompasses a range of services that support the development and production of small molecule drugs, biologics, biosimilars, and active pharmaceutical ingredients (APIs). Services include drug discovery, route scouting, regulatory compliance, clinical trials, outsourcing, drug formulation, quality control, and advanced manufacturing technologies such as continuous manufacturing and specialized services. Artificial Intelligence (AI) is increasingly being utilized in drug discovery to identify new drug candidates and optimize their properties. Cost-effective manufacturing is a key driver for outsourcing, particularly for generic drugs and APIs. Bioprocess outsourcing is essential for the production of complex biologics and biosimilars. Continuous manufacturing offers advantages in terms of cost savings, improved quality, and increased efficiency. Specialized services include the production of low potent APIs and the manufacturing of originator and generic APIs. The market caters to both small molecule drugs and biologics, with a focus on ensuring regulatory compliance and maintaining the highest standards of quality control.

Market Research Overview

The Pharmaceutical Contract Research and Manufacturing (CRM) market encompasses a range of services that support the entire drug development process, from discovery to commercialization. This market includes various services such as drug discovery, clinical trials, regulatory compliance, route scouting, bioprocess outsourcing, and manufacturing services. Generic Drugs: CRM companies offer manufacturing services for generic drugs, producing affordable alternatives to branded medicines. Artificial Intelligence: AI is increasingly used in drug development to identify new targets, optimize drug design, and analyze clinical trial data. Drug Development: CRM companies provide comprehensive drug development services, from discovery to commercialization, ensuring regulatory compliance and cost-effective manufacturing. Clinical Trials: CRM companies offer clinical trial support, managing trial design, execution, and data analysis to ensure efficient and effective trials. Outsourcing: Pharmaceutical companies outsource various aspects of drug development and manufacturing to CRM companies for cost savings and expertise. Bioprocess Outsourcing: CRM companies specialize in bioprocessing, producing biologics, biosimilars, and vaccines using advanced manufacturing technologies. Serialization and Counterfeiting: CRM companies provide serialization services to ensure product authenticity and combat counterfeiting, enhancing patient safety. Pharmaceutical Ecosystem: CRM companies operate within the complex pharmaceutical ecosystem, collaborating with academic institutes, CROs, and big pharma to bring new drugs to market. Drug Development Services: CRM companies offer a range of drug development services, from drug discovery and formulation to manufacturing and commercialization. Manufacturing Services: CRM companies provide manufacturing services for small molecule drugs, APIs, and drug delivery systems, ensuring quality control and cost savings. Cost-effective manufacturing: CRM companies offer cost-effective manufacturing solutions, utilizing economies of scale and advanced technologies to reduce production costs. Quality control: CRM companies prioritize quality control, implementing rigorous standards and advanced technologies to ensure product safety and efficacy. Advanced manufacturing technologies: CRM companies employ advanced manufacturing technologies, such as continuous manufacturing and specialized services, to improve efficiency and reduce costs. Personalized medicines: CRM companies support the development and manufacturing of personalized medicines, tailoring treatments to individual patient needs. Drug development processes: CRM companies optimize drug development processes, from production workflows to digitalization, to bring new drugs to market faster and more efficiently.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ServiceCMOCROEnd-userBig PharmaceuticalsSmall And Medium-sized PharmaceuticalsGeneric PharmaceuticalsGeographyNorth AmericaAsiaEuropeRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmaceutical-contract-research-and-manufacturing-market-to-grow-by-usd-141-3billion-from-2024-2028–driven-by-cost-efficient-resources-in-emerging-markets-ai-powered-report—technavio-302267668.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

KIC Ventures Changing the Private Equity Paradigm: The HealthTech Investment Firm with the Most Majority-Owned Portfolio of Revenue-Generating Spine Companies

Published

on

By

KIC Ventures is transforming the private equity landscape in healthtech by focusing exclusively on spine surgery technologies and maintaining majority ownership in its portfolio companies. Unlike traditional firms that diversify minority stakes across various sectors, KIC Ventures’ unique model allows it to control and direct innovation with unparalleled agility. Founded and led by Dr. Kingsley R. Chin, a physician with over 20 years of clinical experience, KIC Ventures disrupts the market by aligning its investments with the future of outpatient spine care. This physician-led approach ensures the firm addresses real clinical needs, giving it a decisive advantage in shaping the future of spine surgery, particularly in physician-owned outpatient centers.

FORT LAUDERDALE, Fla., Oct. 7, 2024 /PRNewswire-PRWeb/ — KIC Ventures is reshaping private equity in healthtech by maintaining majority ownership in the most number of revenue-generating spine companies in the world. Unlike traditional firms that diversify minority stakes across sectors, KIC Ventures exclusively focuses on spine surgery technologies, giving it unparalleled control and agility in driving innovation.

“KIC Ventures is transforming spine care by empowering physicians with cutting-edge technologies, shifting the focus from hospital-based systems to physician-owned outpatient centers for more efficient and patient-centered care.” – Dr. Erik C. Spayde, CMO of KIC Ventures

Led by founder Dr. Kingsley R. Chin—a Harvard-trained orthopedic spine surgeon and Harvard Business School graduate—KIC Ventures’ leadership team consists of experts who invest their own capital, ensuring a stable and committed group that can act with speed and decisiveness. This unique approach has enabled KIC Ventures to maintain majority ownership, allowing the firm to predict market needs and align investments with the future of outpatient spine care.

KIC Ventures’ proprietary Less Exposure Spine Surgery (LESS) philosophy, pioneered by Dr. Chin, focuses on less invasive procedures that preserve anatomy, reduce recovery times, and empower physicians. This innovative, patient-centered approach places KIC Ventures ahead of traditional hospital-based models, positioning it as a key disruptor in the spine surgery market.

Strategic Milestones and Global Vision

KIC Ventures’ journey is marked by significant milestones that demonstrate its ability to identify and scale breakthrough technologies. The sale of MANTIS to Stryker and acquisitions like AxioMed and NanoFuse Biologics underscore its vision for developing innovative solutions that meet the evolving needs of surgeons and outpatient facilities. With its leadership in spine care technologies, KIC Ventures continues to challenge traditional healthcare models by supporting physician-owned outpatient centers.

“We are proud to lead the outpatient spine surgery market, offering cutting-edge solutions that empower physicians and transform care from hospital-based systems to physician-owned centers,” said Dr. Erik C. Spayde, Chief Medical Officer of KIC Ventures, Chief of Spine Surgery at a major California Hospital and Harvard-trained board-certified orthopedic spine surgeon

Looking ahead to 2025, KIC Ventures plans to release new spine surgery innovations, including the highly anticipated Axiomed lumbar disc, and expand its NANISX portfolio, which already features technologies like InSpan, Sacrix, and FacetFuse. The firm’s ability to remain nimble and act with foresight is a direct result of its capital strategy and leadership stability. “Our independent capital strategy allows us to act with decisiveness, avoiding dilution and keeping our leadership agile,” added Aditya Humad, Co-founder, President, and CFO of KIC Ventures, formerly at JP Morgan HealthTech mergers and acquisitions, and a graduate of Wharton and Harvard Business School.

Chief Technology Officer Vito Lore also emphasized the firm’s commitment to collaboration. “Collaboration between engineers and physicians drives our innovation. Our upcoming 2025 releases are set to shape the future of spine care technologies.” Lore, with a background in aeronautical engineering from Purdue University and almost two decades of experience in spine innovations, brings deep experience collaborating with physicians to the firm’s cutting-edge advancements.

A Vision for the Future

KIC Ventures is built on Dr. Chin’s entrepreneurial philosophy of identifying a Problem, predicting future needs, and creating products that drive global adoption—his “3 P’s of entrepreneurship.” This strategy has fueled the firm’s growth and innovation. With new product launches on the horizon, KIC Ventures is set to continue leading the transformation of outpatient spine surgery worldwide.

About KIC Ventures
Founded in 2013 as the venture arm of Kingsley Investment Company LLC, KIC Ventures focuses exclusively on advancing outpatient spine surgery through its Less Exposure Spine Surgery (LESS) philosophy. With a portfolio of innovative spine technologies and a commitment to empowering physicians, KIC Ventures has become the world’s largest private equity firm with a majority-owned portfolio of differentiated spine companies focused on outpatient spine solutions.

For more information, visit http://www.kicventures.com.

Media Contact

KIC Ventures, KIC Ventures, 978-232-3990, Press@KICVentures.com, www.KICVentures.com 

Twitter

View original content to download multimedia:https://www.prweb.com/releases/kic-ventures-changing-the-private-equity-paradigm-the-healthtech-investment-firm-with-the-most-majority-owned-portfolio-of-revenue-generating-spine-companies-302269346.html

SOURCE KIC Ventures

Continue Reading

Technology

AMI Partners with Samsung to Bring Firmware Security to PCs

Published

on

By

ATLANTA, Oct. 8, 2024 /PRNewswire/ — AMI®, the global leader in Dynamic Firmware for worldwide computing, has partnered with Samsung Electronics, the global leader in consumer technology, to create an enhanced joint security solution available in Samsung’s Galaxy Book PCs. Alongside Samsung’s multi-layer security platform Samsung Knox, AMI’s Tektagon™ – the industry-leading Platform Root of Trust firmware security solution – is now integrated into Samsung PCs including the Galaxy Book5 Pro 360, Galaxy Book4 Pro, Galaxy Book4 Pro 360, and Galaxy Book4 Ultra. 

Through this collaborative partnership, AMI’s Tektagon seamlessly integrates with Samsung Knox to ensure that confidential and sensitive data stays safe at every layer of the device through real-time threat detection and collaborative protection, while providing the highest level of security against firmware-injected malware to help prevent ransomware and denial of service attacks.

“As a leading supplier of endpoint technology to global government and commercial industries, Samsung is committed to securing its platforms at all levels,” said Dr. Hark-Sang Kim, EVP & Head of New Computing R&D Team, Mobile eXperience Business at Samsung Electronics. “Integrating AMI’s Tektagon solution into our latest Galaxy Books provides powerful and comprehensive protection at the platform’s foundation.”

The Samsung Knox platform leverages the motherboard’s existing embedded processor to provide a hardware-backed secure platform, which includes AMI’s Tektagon security technology. Thanks to AMI’s leading capabilities as a firmware provider, the need for additional components is reduced while hardware-rooted security is still seamlessly delivered.

“AMI is extremely proud of our work integrating our Tektagon Platform Root of Trust solution into Samsung Galaxy Book series notebooks,” said Stefano Righi, Senior Vice President of the AMI Global Software and Security Group. “Together Samsung and AMI are helping to reduce the cyber threat landscape, securing business endpoints around the world from malicious attacks.”

The Samsung Galaxy Book5 Pro 360, Galaxy Book4 Pro, Galaxy Book4 Pro 360 and Galaxy Book4 Ultra with AMI Tektagon Platform Root of Trust are available today and can be ordered directly from Samsung.

Follow AMI on LinkedIn and Twitter/X to receive the latest news and announcements.

AMI® and Tektagon™ are registered trademarks/trademarks of AMI in the US and/or elsewhere. Galaxy Book and Knox are trademarks of Samsung Electronics Co. Ltd. in the United States and other countries. All other trademarks and registered trademarks are the property of their respective owners.

About AMI

AMI is Firmware Reimagined for modern computing. As a global leader in Dynamic Firmware for security, orchestration, and manageability solutions, AMI enables the world’s compute platforms from on-premises to the cloud to the edge. AMI’s industry-leading foundational technology and unwavering customer support have generated lasting partnerships and spurred innovation for some of the most prominent brands in the high-tech industry.

Logo – https://mma.prnewswire.com/media/1327926/AMI_Logo2023.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ami-partners-with-samsung-to-bring-firmware-security-to-pcs-302269372.html

Continue Reading

Technology

Patriot Memory Unveils Viper PV573 Gen5 SSD: Compact Design, Maximum Power–The Perfect Balance of Size and Performance

Published

on

By

TAIPEI, Oct. 8, 2024 /PRNewswire/ — Patriot Memory, a leading manufacturer of high-performance gaming memory modules, SSDs, flash memory, and gaming peripherals, today announced the launch of its latest innovation under the Viper Gaming brand: the Viper PV573 PCIe Gen5 x4 M.2 2280 SSD. This product reinforces Patriot’s leadership in cutting-edge technology, pushing speed boundaries beyond its predecessor, the PV553.

The Viper PV573 SSD utilizes advanced 3D NAND vertical stacking technology, significantly enhancing storage density while reducing power consumption and delivering faster read and write speeds. This innovation also improves durability, making it a reliable choice for users with demanding storage needs. With capacity options of up to 4TB, the Viper PV573 combines powerful performance in a compact, portable form factor, achieving the perfect balance of high capacity and efficiency within a small footprint.

The Viper PV573 SSD boasts astonishing read speeds of up to 14,000 MB/s and write speeds of 12,000 MB/s. Equipped with Patriot’s proprietary active cooling technology, it is specifically designed for high-performance computers, workstations, data centers, servers, gaming consoles, and media creation and editing applications, ensuring stability and high performance during extended use.

Featuring the latest PCIe Gen5 x4 controller and 232-layer TLC NAND technology, the Viper PV573 is fully compliant with the NVMe 2.0 specification. With blazing read speeds of up to 14,000 MB/s and write speeds reaching 12,000 MB/s, it delivers a performance boost of up to 2.8 times faster than the previous Gen 4 SSD standard and nearly 7 times faster than Gen 3 SSDs. This provides users with an unprecedented speed experience for performance-demanding tasks. Not only is it backward compatible with PCIe 4.0 and PCIe 3.0 platforms, but it also offers exceptional system loading and data caching performance, making it ideal for intensive creative workloads. Whether it’s 3D animation production, game development, or high-complexity virtual visualization, the PV573 effortlessly handles it all, significantly enhancing multitasking efficiency. On the latest Intel and AMD platforms, it showcases unmatched performance, offering creators and gamers the ultimate solution for all high-performance application needs.

The Viper PV573 SSD features Patriot’s most advanced proprietary cooling technology with an active fan design. The fan system, tailored for Gen 5 SSDs, introduces cool air through an aluminum alloy heatsink, creating thermal convection and accelerating heat dissipation, thus improving overall cooling performance by over 40%. The 16.5mm high thermal conductivity aluminum alloy heatsink, with an innovative heat flow design, effectively addresses common overheating issues in Gen 5 SSDs, ensuring stable temperatures under high-load operations.

The Viper PV573 Gen5 x4 SSD is equipped with powerful data protection and error correction mechanisms that significantly enhance the durability of NAND storage while ensuring data integrity and stable system operation. By incorporating advanced wear leveling technology, the SSD’s lifespan is greatly extended. It also features 4K LDPC (Low-Density Parity-Check) error correction technology, which maintains consistently high performance even under prolonged, high-load operation.

Additionally, the Viper PV573 comes with a comprehensive five-year global warranty, offering users peace of mind for high-performance applications such as gaming, video editing, 3D modeling, and rendering. This ensures reliable, long-term support for demanding tasks.

This new SSD not only represents an evolution in speed but also showcases Patriot’s relentless pursuit of cutting-edge technology, delivering the perfect combination of ultimate speed and stability for all high-performance applications.

About Patriot Group

Patriot Group designs, develops, manufactures, and markets high-performance memory and storage products and solutions, streamlining users and technologies of data applications for different verticals. The Patriot Group owns three leading brands, Patriot, Viper Gaming, and ACPI, serving different market segments. Patriot offers the latest consumer memory and storage technologies, including DRAM, SSD, and flash memories. Viper Gaming features top-notch overclock-ready memories and gaming gadgets that appeal to hardcore gamers, covering high-performance memory modules and SSDs to the latest in gaming accessories. ACPI, the group’s brand for industrial-grade storage solutions, provides flash storage devices for industrial applications and embedded systems with reliability and quality.

About Viper™

Viper™ is a trademarked brand under the Patriot Group, a global leader in performance memory, SSD, and flash storage solutions. Established in 2007, Viper™ made its mark by introducing a renowned line of computer memory. This line has since become synonymous with elite performance and reliability among gamers worldwide. In 2015, Viper™ expanded its product range to include gaming keyboards, headsets, and mice. With offerings in entry-level, mid-level, and high-end categories, all equipped with rich feature sets, Viper™ has garnered numerous awards for its peripherals. These accolades are a testament to the brand’s commitment to providing gamers with unrivaled performance and reliability, empowering them to dominate their chosen sport.

*All company and/or product names may be trade names, trademarks and/or registered trademarks of the respective owners with which they are associated. Features, pricing, availability, and specifications are subject to change without notice.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/patriot-memory-unveils-viper-pv573-gen5-ssd-compact-design-maximum-powerthe-perfect-balance-of-size-and-performance-302268680.html

SOURCE Patriot Memory

Continue Reading

Trending